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KEY PO INT S
l Bone marrow-specific
deletion of Abi1 in
mice results in MPN-
like phenotype and is
linked to hyperactive
SFKs/STAT3/NF-kB
signaling.
l ABI1 is downregulated
in hematopoietic
stem/progenitor cells
and granulocytes from
patients with PMF.
Although the pathogenesis of primary myelofibrosis (PMF) and other myeloproliferative
neoplasms (MPNs) is linked to constitutive activation of the JAK-STAT pathway, JAK in-
hibitors have neither curative nor MPN-stem cell-eradicating potential, indicating that
other targetable mechanisms are contributing to the pathophysiology of MPNs. We
previously demonstrated that Abelson interactor 1 (Abi-1), a negative regulator of Abelson
kinase 1, functions as a tumor suppressor. Here we present data showing that bone
marrow-specific deletion ofAbi1 in a novel mouse model leads to development of anMPN-
like phenotype resembling human PMF. Abi1 loss resulted in a significant increase in the
activity of the Src family kinases (SFKs), STAT3, and NF-kB signaling. We also observed
impairment of hematopoietic stem cell self-renewal and fitness, as evidenced in non-
competitive and competitive bone marrow transplant experiments. CD341 hematopoietic
progenitors and granulocytes from patients with PMF showed decreased levels of ABI1
transcript as well as increased activity of SFKs, STAT3, and NF-kB. In aggregate, our data
link the loss of Abi-1 function to hyperactive SFKs/STAT3/NF-kB signaling and suggest that this signaling axis may
represent a regulatory module involved in the molecular pathophysiology of PMF. (Blood. 2018;132(19):2053-2066)
Introduction
The phenotype of primary myelofibrosis (PMF) is characterized by
progressive bone marrow fibrosis, organomegaly, extramedullary
hematopoiesis, thromboembolism, and ultimately, marrow failure
or transformation to acute myeloid leukemia (AML).1-3 Median
survival in PMF varies between 1 and 15 years, depending on risk
factors, and treatment options are limited.3,4 Identification of
JAK2-activating mutations as major drivers in myeloproliferative
neoplasms (MPNs) prompted clinical development of JAK2
inhibitors.5,6 Ruxolitinib, an ATP-mimetic JAK1/2 inhibitor, in-
duces symptomatic improvement in PMF, but exacerbates as-
sociated cytopenias and does not have curative potential, and
responses occur regardless of presence of JAK2 mutations.7-11
Therefore, a major need remains to identify other targetable
mechanisms contributing to the pathogenesis of PMF and related
MPNs, polycythemia vera (PV), and essential thrombocythemia
(ET).
Abelson Interactor 1 (Abi-1) is a negative regulator of Abl1
kinase,12-15 involved in regulation of cell proliferation.16,17 By
forming a complex with Wiskott-Aldrich syndrome protein family
member 2 (WAVE2),18,19 Wiskott-Aldrich Syndrome protein
(WASP), or Diaphanous (Dia) formin,16,18-23 Abi-1 affects actin
remodeling, cell adhesion, and migration. Abi-1 also inter-
acts with integrin a4 and is involved in integrin b1 signaling.24-26
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Abi-1-deficient mice uniformly die in utero with lethal defects of
the heart and placenta.19,24 The role of Abi-1 in carcinogenesis
is controversial, as both loss or overexpression were implicated
in cancer.27-30 Its involvement in malignant hematopoiesis, al-
though reported by us and others, remains unclear.31-35
Here, we present evidence for direct involvement of Abi-1 in
homeostasis of hematopoietic system. We found that condi-
tional deletion of Abi1 in murine bone marrow results in im-
pairment of hematopoietic stem cell self-renewal, progressive
anemia, megakaryocytosis and myeloid hyperplasia, with
resulting PMF-like phenotype characterized by marrow fibrosis
and splenomegaly. Furthermore, Abi-1 protein andmRNA levels
are decreased in hematopoietic progenitors from patients with
PMF, but not from those with ET or PV. Mechanistically, loss of
Abi-1 leads to upregulation of Src family kinases (SFKs), STAT3,
and NF-kB signaling, suggesting that the Abi-1/SFKs/STAT3/
NF-kB axis may represent a new regulatory module involved in
the pathophysiology of MPNs.
Materials and methods
Patient samples
CD341 cells were isolated from the bonemarrow of patients with
PMF or from healthy marrow purchased from AllCells (Alameda,
CA). Granulocytes were isolated from peripheral blood (PB) of
patients with ET, PV, primary or secondary (PV- or ET-derived)
myelofibrosis, and healthy donors (supplemental Table 1, available
on the BloodWeb site). CD34 MicroBeads (Miltenyi Biotec, San
Diego, CA) and gradient centrifugation were used for CD341
and granulocyte isolation, respectively. Human subject partici-
pation was conducted with informed consent and approved by
local ethics committees.
Transgenic mice
Conditional Abi1(fl/fl) mice19 were crossed with B6.Cg-
Tg(Mx1-cre11)Cgn/J strain (#003556, JAX, Bar Harbor, ME)36
to generate Abi1(fl/fl);Tg(Mx1-cre[1/2]) mice. These animals
were back-crossed to B6.SJL-PtprcAPepcB/BoyJ(#002014, JAX)
(CD45.1) background. Abi1(fl/fl);Tg(Mx1-cre[2]), Abi1(fl/wt);
Tg(Mx1-cre[1]), or Abi1(fl/fl);Tg(Mx1-cre[1]) mice were subjected
to polyinosinic:polycytidylic acid [poly(I:C)]-induced (Invivo Gen,
San Diego, CA) activation of the Cre recombinase under the
control of Mx1 promoter to obtain animals with an Abi1(fl/fl);Tg
(Mx1-cre[2]), Abi1(2/wt);Tg(Mx1-cre[2]), or Abi1(2/2);Tg(Mx1-
cre[1]) genotype, designated as Abi-1WT, Abi-1HET, or Abi-1KO, re-
spectively. Recombination of Abi1floxed allele was confirmed by
polymerase chain reaction (PCR). We evaluated 76 Abi-1WT,
41 Abi-1HET, and 85 Abi-1KO animals. Animal experiments were
approved by the Institutional Animal Care and Use Committee.
Murine hematopoietic stem/progenitor
cells isolation
A biotin-conjugated antibody cocktail containing anti-TER119,
CD127, CD8a, Ly-6G, CD11b, CD4, and CD45R was used to
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Figure 1. ABI1 is downregulated in hematopoietic progenitor cells and granulocytes obtained from patients with MPNs. (A) Reverse transcription (RT)-PCR analysis of
ABI1 transcript levels in CD341 cells isolated from the bone marrow aspirates of patients with PMF (n 5 5) or healthy control patients (n 5 5). ABI1 gene expression was
normalized to RPP14 (RNaseP) andACTB. (B) RT-PCR analysis ofABI1 gene expression in peripheral blood granulocytes from patients with PMF (n5 36), ET (n5 15), PV (n5 20),
myelofibrosis post-ET (n 5 5), and post-PV (n 5 9) or from healthy controls (n 5 16), normalized to RPP14. (C) RT-PCR analysis of ABI1 gene expression in peripheral blood
granulocytes from patients with PMF with JAK2 (JAK2 V617F) or CALR mutations (Del52 or Ins5), normalized to RPP14. Clinical details of the analyzed samples are presented in
supplemental Table 1. Boxes represent the interquartile range that contains 50% of the subjects, and the horizontal line in the box indicates the median. *P , .05, ***P , .001.
2054 blood® 8 NOVEMBER 2018 | VOLUME 132, NUMBER 19 CHORZALSKA et al
For personal use only.on March 29, 2019. by guest  www.bloodjournal.orgFrom 
stain lineage-committed cells. BUV395-Streptavidin, anti-CD34-
FITC, CD117/c-Kit-APC, Ly-6A/E/Sca-1-PE-Cy7 (or -BV605),
CD135/Flt3-PE, and CD16/CD32-PE were used to stain hema-
topoietic stem/progenitors. Cells were sorted using Legacy
MoFlo High-Speed cell sorter.
Bone marrow transplantation
For noncompetitive bone marrow transplantation, 5 3 106
marrow cells isolated by flushing from poly(I:C)-uninduced
Abi1(fl/fl);Tg(Mx1-cre[1]) or Abi1(fl/fl);Tg(Mx1-cre[2]; CD45.1)
mice were injected via tail vein into lethally irradiated (2x475cGy)
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Figure 2. Transgenic Abi-1KOmice show splenomegaly, leukocytosis, thrombocytosis, and decreased survival. (A) Schematic representation of the experimental design of
deleting Abi1flox allele in Abi1(fl/fl);Tg(Mx1-cre)(1) mice by poly(I:C) induction. Analyses were conducted on animals at 14, 35, or 56 weeks of age (4, 25, or 46 weeks after
recombination, respectively). (B) Genomic PCR analysis of Abi1flox deletion efficiency in tail (top) and bone marrow (bottom) DNA. PCR amplification of the mutated, LoxP site
containing Abi1 allele produces a 359-nt band, recombined Abi1 allele produces no band, and nonmutated wild type Abi-1 allele produces a 179-nt band. A locus map is
presented in supplemental Figure 2A. Tissue from 3 different Abi-1WT, Abi-1HET, and Abi-1KO animals was used. (C) Western blot analysis of Abi-1 protein levels in the bone
marrow of Abi-1WT, Abi-1HET, and Abi-1KO mice. Tissue from 3 different animals per group was used. (D) Representative gross anatomy of femurs and spleens of 14-, 35-, and 56-
week-old Abi-1WT or Abi-1KO animals. (E) Average spleen and liver sizes of Abi-1WT and Abi-1KO mice. Relative organ weight was calculated as an absolute organ weight (g)/body
weight on sacrifice day (g)3100. Organs from n5 12 sex-matched animals were evaluated per age group. (F) Average white blood cells count, hematocrit values, and platelet
count of the peripheral blood obtained from 14-, 35-, and 56-week-old Abi-1WT or Abi-1KO animals performed using automated hematology analyzer. Peripheral blood from at
least 12 sex-matchedmice was analyzed per each age group. *P, .05, **P, .01, ***P, .001. (G) Survival of Abi-1WT (n5 48) or Abi-1KO (n5 60) animals monitored from birth for
67 weeks (log-rank P 5 .003).
LOSS OF ABI-1 INDUCES MYELOPROLIFERATIVE NEOPLASM blood® 8 NOVEMBER 2018 | VOLUME 132, NUMBER 19 2055
For personal use only.on March 29, 2019. by guest  www.bloodjournal.orgFrom 
0
14 35 56 weeks
10
20
B2
20
+
 ce
lls
 in
 P
B 
(%
)
40
30
* *
Abi-1 WT Abi-1 KO
0
14 35 56 weeks
10
20
CD
3+
 ce
lls
 in
 P
B 
(%
) 40
30
Abi-1 WT Abi-1 KO
0
14 35 56 weeks
40
20
60
CD
11
b+
/G
r-1
+
 ce
lls
 in
 P
B 
(%
)
80
*
*
*
Abi-1 WT Abi-1 KO
A
Abi-1 KO
56
 w
ee
ks
Abi-1 WT
B
Abi-1 KO
BONE MARROW
SPLEEN
56
 w
ee
ks
56
 w
ee
ks
Abi-1 WT
C
0
14 35 56 weeks
8
4
12
M
eg
ak
ar
yo
cy
te
s p
er
 h
pf
(sp
le
en
/re
d 
pu
lp
) 16
*
*
Abi-1 WT Abi-1 KO
0
14 35 56 weeks
10
20
M
eg
ak
ar
yo
cy
te
s p
er
 h
pf
(b
on
e 
m
ar
ro
w)
30
*
*
*
Abi-1 WT Abi-1 KO
E
Abi-1 KO
BONE MARROW
SPLEEN
56
 w
ee
ks
56
 w
ee
ks
Abi-1 WT
D
0
14 35 56 weeks
10
20
M
ac
ro
ph
ag
es
 w
ith
 h
em
os
id
er
in
in
 th
e 
sp
le
en
/re
d 
pu
lp
 (%
)
30
* *
Abi-1 WT Abi-1 KO
0
14 35 56 weeks
4
8
M
ac
ro
ph
ag
es
 w
ith
 h
em
os
id
er
in
in
 th
e 
bo
ne
 m
ar
ro
w 
(%
)
12
* *
Abi-1 WT Abi-1 KO
F
Abi-1 KO
BONE MARROW
SPLEEN
56
 w
ee
ks
56
 w
ee
ks
Abi-1 WT
G
Figure 3. Abi-1 deficiency results in age progressive increase in circulating granulocytes, anisopoikilocytosis, megakaryocytosis, loss of stainable iron, and fibrosis. (A)
Fluorescence-activated cell sorter analysis of CD11b1/Gr-11, B2201, andCD31 populations in the peripheral blood of Abi-1WT andAbi-1KOmice, performed at 14, 35, or 56 weeks
of age, 20 Abi-1WT and 20 Abi-1KO sex-matchedmice were evaluated at each point. (B) Wright staining of representative blood smears obtained fromAbi-1KO and Abi-1WT mice at
56 weeks of age; teardrop cells are marked with arrows. Similar results were observed in blood smears of at least 12 sex-matched Abi-1WT or Abi-1KO mice. Magnification3100,
bars correspond to 20 mm. Images were obtained using a Zeiss Axiophot microscope and Zeiss Pan-Apochromat 1003/1.40 oil lens. Representative (C) hematoxylin and eosin or
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C57BL/6 wild-type mice recipients (CD45.2; #000664, JAX).
Four weeks posttransplant, Abi1 inactivation was performed
by poly(I:C) induction. Donor chimerism was evaluated in PB
every 4 weeks for 24 weeks. After 24 weeks, marrow was har-
vested from primary recipients and 5 3 106 cells were trans-
planted into CD45.2 secondary recipients conditioned as earlier.
Donor chimerism in PB was evaluated as earlier. For competitive
repopulation assays, marrow cells were isolated via flushing
from poly(I:C)-induced Abi-1KO or Abi-1WT (CD45.1) mice. After
confirming Abi1 inactivation, donor cells (1 3 106 Abi-1KO or
Abi-1WT) were mixed with competitor cells (13 106; 1:1, CD45.1:
CD45.2) and injected via tail vein into lethally irradiated
CD45.2 recipients. Donor chimerism in PB was evaluated as
earlier.
Cytokine levels assay
Levels of interleukin (IL)-1a, IL-1b, IL-6, IL-10, IL-12p70, IL-17A,
IL-23, IL-27, monocyte chemoattractant protein-1 (MCP-1/
CCL2), interferon (IFN)-b, IFN-g, tumor necrosis factora (TNFa),
and granulocyte-macrophage colony-stimulating factor were de-
tected in plasma of Abi-1WT (n5 11) or Abi-1KO (n 5 11) 14-week-
old animals, using LEGENDplex Mouse Inflammation Panel
(Biolegend, San Diego, CA).
ABI1 silencing in human CD341 cells
Healthy CD341 cells (n 5 3) were expanded for 48 hours in the
presence of thrombopoietin, Flt3/Flk-2 (Fms-like tyrosine kinase
3/fetal liver kinase-2) ligand, stem cell factor, IL-3, IL-6, and
granulocyte-macrophage colony-stimulating factor (StemCell
Technologies, Cambridge, MA) and incubated for additional
48 hours with 15 mM ABI1-silencing antisense 29-deoxy-29fluoro-
b-D-arabinonucleotides (FANA-ABI1-ASO; AUM BioTech, Phil-
adelphia, PA). After 48 hours culture with FANA-ABI1-ASO,
Abi-1 protein levels were evaluated by immunoblotting, and cell
cycle status was determined by 5-ethynyl-29-deoxyuridine (EdU)
incorporation assay.
Liquid chromatography-tandem
mass spectrometry
Bone marrow was isolated from 20-week-old Abi-1WT (n 5 3) or
Abi-1KO (n 5 3) animals by flushing. Cell pellets were lysed, and
100 mg protein per sample was subjected to tryptic digestion.
Tryptic peptides were subjected to liquid chromatography-
tandem mass spectrometry, using an automated proteomic
technology platform.37,38
Gene microarrays
Gene array analysis of lineage2, Sca-11, c-Kit1 (LSK)-enriched
cells from 14-week-old Abi-1KO (n 5 4) or Abi-1WT (n 5 5) mice
was done using the Affymetrix-WT Pico Expression Kit (Affy-
metrix, Louisville, KY) and Affymetrix-3000 7G gene scanner.
Partek Genomics Suite v6.6 was used for quality control and data
analysis. Microarray data are deposited in GEO as GSE83288.
Abi-1HET bone marrow transplant model of
MPLW515L-mediated MPN
MSCV-MPLWT-IRES-GFP and MSCV-MPLW515L-IRES-GFP retro-
viral vectors were generously provided by Ross Levine (Memorial
Sloan Kettering Cancer Center). Marrow was isolated from 14-
week-old Abi-1WT or Abi-1HET animals, and Abi1 recombination
was verified by PCR. Retroviral transduction and murine marrow
transplant assay were performed as previously described.39,40 Abi-
1WT/MPLWT, Abi-1HET/MPLWT, Abi-1WT/MPLW515L, and Abi-1HET/
MPLW515L transplantation groups were used.
Statistics
Two-tailed unpaired t-tests or log-rank tests were used for
between-group comparisons, using Bonferroni correction where
appropriate. P , .05 was considered statistically significant.
Throughout, *P , .05, **P , .01, and ***P , .001. Two-tailed
unpaired t-test and q-values for multiple hypothesis tests, using
the R package QVALUE,41 were used to select peptides with
significant change in paired analyses.
Additional materials and methods are described in supple-
mental Information.
Results
Downregulation of ABI1 transcripts in human
PMF samples
ABI1 transcript levels in CD341 cells isolated from bone marrow
were decreased by approximately 40% in PMF (n5 5) compared
with controls (n5 5; Figure 1A). Gene expression profiles (GEO/
GSE53482)42 of CD341 cells isolated from PB also showed
significant downregulation of ABI1 in PMF (n 5 42) with mu-
tations in JAK2 or CALR relative to controls (n 5 31; supple-
mental Figure 1A-C). Furthermore, granulocytes from patients
with PMF (n 5 36), or secondary myelofibrosis post-PV (n 5 9),
showed a 40% to 60% decrease inABI1mRNA relative to control
patients (n 5 16; Figure 1B). Downregulation of ABI1 in PMF
granulocytes was observed regardless of JAK2 or CALR muta-
tion status (Figure 1C). Notably, no significant changes in
granulocyte ABI1 transcript levels were noted in ET (n 5 15), PV
(n 5 20), or post-ET myelofibrosis (n 5 4; Figure 1B). Consistent
with these findings, examination of gene expression profiles of
CD341 cells from bone marrow of ET (n 5 24) and PV (n 5 26)
patients (GEO/GSE103176)43 showed no downregulation of
ABI1 (supplemental Figure 1D), indicating that reduced ABI1
expression may be specific to PMF.
Inactivation of Abi1 in bone marrow induces
leukocytosis, thrombocytosis, anemia,
splenomegaly, and decreased survival
To determine the role of Abi-1 in the homeostasis of the he-
matopoietic system, we phenotyped transgenic Abi-1KO mice
carrying bone marrow-selective knockout of Abi1. We first
confirmed both inducible inactivation of the Abi1flox allele and
Figure 3 (continued) (D) Prussian blue stains of bonemarrow from femurs and spleen sections of 56-week-old Abi-1WT or Abi-1KO animals. Similar results were observed in at
least 12 sex-matched Abi-1WT or Abi-1KO mice. Bars correspond to 100 mm. Images were obtained using a Zeiss Axiophot microscope with Zeiss Pan-Apochromat 203/1.0
lens. (E) Average number of megakaryocytes per high power field (hpf) and (F) percentage of macrophages with hemosiderin in the bone marrow and spleen/red pulp
evaluated in 14-, 35-, and 56-week-old Abi-1WT or Abi-1KO animals; 6 sex-matched animals were evaluated per age group per genotype. Representative (G) Gomori reticulin
staining of the bone marrow from femurs and spleen sections of 56-week-old Abi-1WT or Abi-1KO animals (black stain). Similar results were obtained for at least 12 sex-
matched animals per group. Bars correspond to 100 mm. Images were obtained using Zeiss Axiophot microscope with Zeiss Pan-Apochromat 203/1.0 lens. *P , .05.
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loss of Abi-1 protein in the marrow (Figure 2A-C; supplemental
Figure 2A-B). Abi-1 levels were also reduced in spleen and
liver, but not in heart, lung, or kidney (supplemental Figure 2C).
Abi-1KO mice showed femur pallor and splenomegaly that
progressed with age, but no change in liver size (Figure 2D-E).
Blood count analysis at 14, 35, and 56 weeks indicated progressive
leukocytosis, mild anemia, and thrombocytosis in the Abi-1KO,
which were absent in Abi-1WT animals (Figure 2F; supplemental
Table 2). Survival of Abi-1KOmicedecreased20weekspost-poly(I:C)
injection, with significant weight loss after 60 weeks and death in all
animals by 66 weeks of age (Figure 2G; supplemental Figure 2D),
likely because of progressive disease. We observed no changes
in gross pathology, blood counts, or survival in 56-week-old
Abi-1HET animals. Therefore, in subsequent analyses, we fo-
cused on characterization of Abi-1KO mice. Our findings sug-
gest that marrow-specific inactivation of Abi1 disrupts normal
hematopoiesis.
Abi-1 loss results in myeloid hyperplasia,
megakaryocytosis, and fibrosis
As Abi-1KO animals aged, the fraction of myeloid (CD11b1/Gr-11)
cells in their PB increased at the expense of lymphoid B220
cells, whereas the CD31 lymphoid fraction remained un-
changed (Figure 3A). Abi-1KO erythrocytes demonstrated
polychromasia, anisopoikilocytosis, and teardrop-shaped
forms (Figure 3B; supplemental Figure 3A). Giant platelets
were observed in 2/10 14-week-old, 4/10 36-week-old, and 5/10
56-week-old or older Abi-1KO mice. Bone marrow showed
hypercellularity with myeloid hyperplasia, erythroid hypoplasia,
and megakaryocytosis (Figure 3C-E; supplemental Figure 3B-C).
Bone marrow cellularity at the distal aspect of femur in the
medial and lateral condyles was 95% for Abi-1WT and 100% for
56-week-old Abi-1KO mice (supplemental Figure 3D). Spleen
histology showed expansion of red pulp, with numerous is-
lands of megakaryocytic, myeloid, and erythroid infiltra-
tion (Figure 3C-D; supplemental Figure 3B-C). Clusters of
megakaryocytes were commonly observed in marrow and
spleen of 56-week-old Abi-1KO mice (supplemental Figure 3C).
Abi-1KO marrow samples and spleens showed progressive
deficits of stainable iron on Prussian blue staining (Figure 3D
and 3F; supplemental Figure 4A-B), possibly linked to ob-
served anemia (supplemental Table 2; Figure 2F). Silver stain
and semiquantitative grading44 showed progressive increase
in reticulin fibrosis in Abi-1KO marrow, from grade 1 (out of 3)
at 14 weeks to grade 2 to 3 at 56 weeks (Figure 3G; sup-
plemental Figure 4C). Increased thickness and density of
reticulin fibers was present in Abi-1KO spleen, from grade 1 at
14 weeks to grade 2 at 56 weeks (Figure 3G; supplemental
Figure 4C). Progressive splenomegaly, megakaryocytosis, and
marrow and spleen fibrosis in Abi-1KO animals meet Mouse
Models of Human Cancers Consortium criteria for MPN.45
Abi-1 deficiency results in increased frequency and
cell cycle activity of hematopoietic stem/
progenitor cells
We assessed the frequency of hematopoietic stem and pro-
genitor cells in the marrow of 14-week-old Abi-1WT or Abi-1KO
mice (supplemental Figure 5A). Deletion of Abi1 resulted in no
change in Lin- fractions. However, there were increased fre-
quencies of LSKs (from 2.3% [60.4%] to 4.6% [60.8%]) and LK
progenitors (from 4.9% [60.9%] to 17.6% [61.1%]; Figure 4A-B),
a 2.6-fold increase in LT-HSCs, no change in ST-HSCs, a 47%
reduction in common myeloid progenitors (CMPs), and a 25%
increase in granulocyte-monocyte progenitors (GMPs) (Figure 4C;
supplemental Figure 5B). Evaluation of the absolute number of
stem/progenitor cells confirmed these trends with the exception
of CMP, which showed an increased number in Abi-1KO mice
(supplemental Figure 5C).
Given this evidence for expansion of HSCs, we evaluated the
cell cycle activity of LSK and LT-HSC cells. Abi-1KO mice at 14
weeks showed a higher proportion of LSK cells in S-phase, and
46% more LT-HSCs in the S/G2/M phases relative to Abi-1WT
animals (Figure 4D-E; supplemental Figure 5D-E). Transcript
expression analysis of genes regulating cell cycle progression
in LT-HSCs confirmed these observations (supplemental
Figure 5F).
To determine the effect of Abi-1 loss on hematopoietic pro-
genitors, we performed colony-forming unit assays. Results showed
a significant decrease in burst forming unit-erythroid and in-
crease in GMP colonies derived from Abi-1KO marrow isolated
from 14-week-old mice, consistent with anemia and leukocytosis
(supplemental Figure 5G). We further observed a 3-fold increase
in megakaryocyte colonies, consistent with the observed mega-
karyocytosis in Abi-1KO mice (supplemental Figure 5H). We found
no indication of growth factor independence or hypersensitivity.
To examine the effect of Abi-1 loss on long-term engraftment
and self-renewal of HSCs, we transplanted bone marrow cells
isolated fromAbi-1WT or Abi-1KOmice (before poly[I:C] injection),
into lethally irradiated recipient C57BL/6 wild-type mice in the
absence of competitor cells. Four weeks after the transplantation,
Abi-1 loss was induced by poly(I:C)-induction. Whereas initial
engraftment remained comparable (;95%) for primary recipients
Figure 4. Expansion, increased cell cycle activity, decreased engraftability and inflammatory signature in Abi-1 deficient hematopoietic stem/progenitor cells. (A)
Frequencies of Lin- cells in 53 105 bonemarrow. (B) Frequencies of LSK or LK cells in lineage-negative fractions of Abi-1WT or Abi-1KO bonemarrow. (C) Frequencies of long-term
(LT)- and short-term (ST)-HSCs and multipotent progenitors in LSK fractions were determined by sorting. Sorting was performed using bone marrow obtained from 6 sex-
matched 14-week-old Abi-1WT or Abi-1KO mice. Sorting strategy is presented in supplemental Figure 5A. Average percentages of (D) EdU-positive LSK cells in G0/G1, S, and G2/
M phase and (E) EdU-positive LT-HSCs in G0/G1 and S/G2/M phase of the cell cycle. Data from 4 experiments each using bone marrow from 14-week-old sex-matched Abi-1WT
or Abi-1KO animals are shown as mean. Noncompetitive bone marrow primary (F) and secondary (G) transplant. Bone marrow cells isolated from Abi-1WT or Abi-1KO mice (before
poly[I:C] injection) were transplanted into lethally irradiated recipient C57BL/6 wild-type mice in the absence of competitor cells. Four weeks after the transplantation, Abi-1 loss
was induced by poly(I:C) administration. Twenty-four weeks posttransplant, bone marrow cells were harvested from primary recipients and transplanted into the secondary
recipients. Average donor chimerism in primary and secondary recipients was monitored every 4 weeks for 24 weeks posttransplantation; n5 4 Abi-1WT or n5 4 Abi-1KO donor
mice (CD45.1) were used for primary or secondary transplants, and 10 recipient lethally irradiated (CD45.2) mice per Abi-1WT orAbi-1KO transplant group were used. (H) Western
blot analysis of Abi-1 protein levels and (I) average percentage of G0/G1, S or G2/M human CD341 cells (n5 3) exposed to FANA ABI1 silencing antisense oligonucleotide (KD)
or scrambled control (Ctrl) for 48 hours. (J) Heat map showing differently expressed transcripts in LSK-enriched cells isolated from the bone marrow of n5 4 Abi-1KO and n5 5
Abi-1WT 14-week-old animals. False discovery rate was , 0.05. (K) Cytokine levels detected in the plasma of 14-weeks old sex-matched Abi-1WT (n 5 12) and Abi-1KO (n 5 12)
animals. *P , .05, **P , .01.
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Figure 5. Abi-1 loss in the bone marrow results in instability of WAVE2 complex, and is accompanied by increased phosphorylation of STAT3, SFKs, and NF-kB.
Western blot evaluation of the activity status of (A) NF-kB and its inhibitor IkB, (B) JAK2, STAT5, STAT3, Erk1/2, Akt, and (C) SFKs using phospho-site-specific antibodies, and (D)
stability of WAVE2 complex components (WAVE2, Nap1, Abi-1, and Sra-1) in Abi-1-deficient bone marrow. Bone marrow from 3 different Abi-1WT and Abi-1KO sex-matched 20-
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of Abi-1WT or Abi-1KO transplants, 12 weeks postpoly(I:C)-
induction, Abi-1KO-transplanted mice showed progressive loss
of chimerism (Figure 4F). These mice also exhibited significant
weight loss at 24 weeks posttransplant, with an average weight
of 22.2 g (61.8 g) compared with 28.6 g (63.1 g) for Abi-1WT
marrow recipients (P 5 .04). Bone marrow cells were harvested
from primary recipients 24 weeks posttransplant and transplanted
into secondary recipients. A further decrease in donor chimerism
and significantly reduced initial engraftment of Abi-1KO bone
marrow cells were seen in secondary recipients (Figure 4G).
In competitive repopulation assays, C57BL/6 wild-type mice
transplanted with the whole bone marrow isolated from Abi-1KO
mice 4 weeks post-poly(I:C)-induction (after PCR confirmed re-
combination) showed progressive decrease in donor chimerism
relative to Abi-1WT marrow recipients, reaching significance
4 months after the transplant (supplemental Figure 5I). Of note,
initial engraftment at 4 weeks posttransplant was comparable
between recipients of Abi-1KO or Abi-1WT marrow (46% and 45%
chimerism, respectively).
To confirm a direct link between Abi-1 loss and cell cycle ac-
tivity in hematopoietic stem/progenitor cells, we performed
EdU incorporation assays using CD341 cells isolated from the
bone marrow of healthy donors (n 5 3) and exposed to ABI1-
silencing FANA antisense oligonucleotides (FANA-ABI1-ASO).
More than 50% efficiency of ABI1 silencing after 48 hours in-
cubation with FANA-ABI1-ASO was noted for CD341 cells
(Figure 4H; supplemental Figure 6A). Cellular penetrance of
FANA oligos was confirmed by confocal microscopy and
fluorescence-activated cell sorting (supplemental Figure 6B-C).
EdU incorporation assays showed that 48-hour exposure to
FANA-ABI1-ASO resulted in a nearly 2-fold increase in CD341
cells in S-phase (Figure 4I; supplemental Figure 6D). Overall,
our data suggest that deletion of Abi-1 leads to abnormal cell
cycle activity, impaired HSC self-renewal, and defective re-
constitution of hematopoiesis.
Activation of NF-kB pathway and pro-inflammatory
signaling in Abi-1KO mice
To determine factors contributing to the abnormal expansion of
hematopoietic stem/progenitor cells in Abi-1-deficient ani-
mals, we performed a genome-wide expression analysis of LSK
cells from 14-week-old Abi-1KO and Abi-1WT mice. We found
significant overexpression of genes regulated by or involved in
regulation of the NF-kB pathway (Figure 4J; supplemental
Table 3). MetaCore Pathway Analysis indicated that the NF-kB
pathway was first of the top 10 dysregulated pathways in the
Abi-1KO LSK cells (supplemental Figure 6E). Ingenuity Pathway
Analysis identified 3 overlapping networks in which NF-kB
activation was predicted on the basis of increased expression
of known NF-kB targets (Cd69, Cxcl10, Cxcl2, Hp, and Nfkbia)
and regulators (Myd88, Chuk, and Ikbkb; supplemental Figure
6F).46,47 Of note, gene expression profiling of CD341 cells from
patients with PMF (GEO/GSE53482) showed upregulation of the
same NF-kB human target genes CXCL10, CD69, and HP (sup-
plemental Figure 7A), as well as genes involved in leukocyte mi-
gration and recruitment (FCER1A, FCER1G, FCGR2A, TPSAB1,
and TPSB2; supplemental Figure 7B).42
We also assessed levels of 13 pro-inflammatory cytokines,
finding a nearly 2-fold increase in IL-1B, IL-12, IL-17, IL-23, IL-27,
and MCP-1/CCL2; a roughly 10-fold increase in IFN-g; and no
significant changes in IL-1A, IL-6, IL-10, TNF a, or IFN-b in Abi-
1KO plasma (Figure 4K). Overall, these data link upregulation of
NF-kB pathway and inflammatory signaling to Abi-1 deficiency
in hematopoietic system.
Abi-1-deficient bonemarrow cells exhibit increased
activity of SFKs, STAT3, and NF-kB
On the basis of our gene expression data indicating active NF-
kB signaling in Abi-1KO marrow, we evaluated major compo-
nents of this pathway by immunoblotting. We found increased
levels of IkB accompanied by increased phosphorylation of
NF-kB (Figure 5A; supplemental Figure 8A). Surprisingly, Abi-
1KO bone marrow showed only modest increase in JAK2 and
STAT5 activities, whereas the phosphorylation of STAT3, Akt,
and Erk1/2 increased significantly (Figure 5B; supplemental
Figure 8B).
On the basis of our previous work showing high-affinity binding
between Abi-1 and the Src homology domain 2 of SFKs, we
assessed the activity of SFKs.48,49 We found increased phos-
phorylation of the Src auto-inhibitory Tyr-527 site. However,
pan-phospho-Src family antibody showed increased phos-
phorylation on Tyr-416, consistent with activation of other
SFKs (Figure 5C; supplemental Figure 8C). We did not detect
phosphorylation of c-Abl on Tyr-412 in Abi-1KO bone marrow
cells (supplemental Figure 8D). Immunoblotting showed an
Abi-1-loss-associated decrease in the stability of WAVE2
complex components (WAVE2, Nap1, and Sra-1; Figure 5D;
supplemental Figure 9A), consistent with our previous
findings.19
To obtain unbiased insight into the mechanistic effects of Abi-1
loss, we performed label-free, intensity-based quantitative
proteomic analysis of bone marrow from 20-week-old Abi-1KO
and Abi-1WT mice. The analysis yielded 12 103 peptides derived
from 2464 unique proteins. When quantified, there were sig-
nificant changes in the abundance of 318 peptides representing
226 unique proteins in the Abi-1KO samples (supplemental
Table 4; supplemental Figure 9B). A volcano plot showed that
Figure 5 (continued) week-old animals was used. (E) Volcano plot of fold change (log 2) vs q-value (2log10) of peak-area for 12 103 peptides identified in Abi-1KO (n 5 3)
respective to Abi-1WT (n5 3) bonemarrow isolated from sex-matched 20-week-old animals. Green represents number of peptides with 2-fold decrease in abundancies, peptides
with 2-fold increase in abundancies are presented in red. (F) Heat map showing significantly changed peptides derived from target proteins known to be associated with MPNs
identified in liquid chromatography-tandemmass spectrometry analysis performed on Abi-1WT or Abi-1KO bonemarrow samples. (G) Immunoblotting assessment of the levels of
Abi-1 and activity status of SFKs, STAT3, andNF-kB in CD341 cells isolated from the bonemarrow of patients with PMF and comparedwith sex- and age-matched healthy control
patients (sample details are presented in supplemental Table 1). Whole-cell lysates were used for immunoblotting analyses. (H) A hypothetical schematic depicting the effect of
Abi-1 on SFKs, STAT3, and NF-kB signaling. Abi-1 acts as a negative regulator of SFKs activity. Its absence leads to overactive SFKs signaling to STAT3, which becomes activated
and cross-activates NF-kB. Overactivity of STAT3 and NF-kB results in cells acquiring inflammatory molecular signature, positively affecting proliferation, survival and ultimately
leading to transformation.
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Figure 6. Loss of 1 copy of Abi-1 accelerates disease development in the bone marrow transplantation model of MPLW515L-mediated myeloproliferative neoplasm. (A)
Schematic representation of Abi-1HET/MPLW515L model. Bonemarrowwas obtained from 14-week-old sex-matchedAbi-1WT (n5 3) or Abi-1HET (n5 3) animals and transducedwith
retrovirus encoding Abi-1WT or W515L mutated GFP-tagged MPL. Infected bone marrows representing 4 experimental groups Abi-1WT/MPLWT, Abi-1HET/MPLWT, Abi-1WT/
MPLW515L, or Abi-1HET/MPLW515L were next transplanted toC57BL/6J females (n5 6 per experimental group). Analyses were conducted 60 days posttransplant. (B). Representative
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among peptides with a more than 2-fold difference, 25.1%
showed lower and 74.9% higher abundance (Figure 5E).
Among peptides showing a greater than 2-fold increase in
abundance in Abi-1KO samples, we detected peptides derived
from calreticulin, CD177, CD97, haptoglobin, Mac-1, myelo-
peroxidase, STAT1, STAT3, and SFKs Hck and Fgr. We
interpreted these data as confirming not only activation of
SFKs and STAT3 signaling but also an increase in proteins
previously associated with MPN. Within the group of peptides
showing a greater than 2-fold decrease in abundance, we
detected peptides derived from WAVE2, Sra-1, and Nap1
(Figure 5F).
Finally, immunoblotting analysis performed on CD341 or CD342
cells isolated from PMF patients showed decreases of 80% and
50% in Abi-1 protein levels, respectively. Similar to Abi-1-depleted
murine marrow, we also found significant upregulation of SFKs and
NF-kB activities (Figure 5G; supplemental Figure 9C-D). These
data indicate that SFKs/STAT3/NF-kB signaling operating in
Abi-1-deficient marrow may be involved in pathogenesis of the
observed PMF-like phenotype. A model of Abi-1/SFKs/STAT3/
NF-kB cross talk is presented in Figure 5H.
Inactivation of 1 copy of Abi-1 accelerates
development of MPLW515L-mediated MPN-
like disease
To further explore the role of Abi-1 in the pathogenesis of MPNs,
we assessed involvement of Abi-1 in 1 of the established models
of the disease. Such models are based on expression of mutated
JAK2, CALR, or MPL. Because of less pronounced ABI1 loss in
granulocytes bearing CALR mutation, and no significant over-
activity of JAK2-STAT5 in Abi-1KOmarrow, we decided to use the
transplant model of MPLW515L-mediated MPN.39 As lethality and
penetrance of the MPLW515L model is variable in C57/BL6 wild-
type mice recipients (in contrast to full penetrance in tumor
growth-permissive Balb/C background),39,50 and homozygous
loss of Abi1 allele is sufficient to produce MPN phenotype, we
decided to use Abi-1HET animals to achieve controllable mani-
festation of the disease in double-mutant (Abi-1HET/MPLW515L)
animals.
Bone marrow isolated from Abi-1WT (n 5 3) and Abi-1HET (n 5 3)
animals was transduced by retrovirus encoding MPLWT or
MPLW515L. Transduction efficiency was higher than 60%. Abi-1WT
marrow cells expressing MPLWT or MPLW515L (Abi-1WT/MPLWT or
Abi-1WT/MPLW515L), or Abi-1HET marrow cells expressing MPLWT
or MPLW515L (Abi-1HET/MPLWT or Abi-1HET/MPLW515L) were trans-
planted into lethally irradiated C57/BL6 mice (n 5 6 per group)
(Figure 6A). Analyses performed 60 days posttransplant showed
no femur pallor or significant changes in spleen or liver sizes
in the Abi-1WT/MPLWT, Abi-1WT/MPLW515L, or Abi-1HET/MPLWT
groups. Conversely, Abi-1HET/MPLW515L animals showed 3-fold
and 1.7-fold increases in spleen and liver size, respectively, as
well as femur pallor (Figure 6B-C). Furthermore, we noted
pronounced leukocytosis, thrombocytosis, and polycythemia in
Abi-1HET/MPLW515L animals compared with Abi-1WT/MPLW515L
(Figure 6D). We also observed a significant increase in Mac-11/
Gr-11, CD41, TER1191/CD711, TER1191/CD712, and B2201
cells in both marrow and blood, and a decrease in CD31 cells
in the marrow of the Abi-1HET/MPLW515L animals (Figure 6E;
supplemental Figure 10A-B). Staining for reticulin fibers in the
Abi-1HET/MPLW515L mice showed significant (31) thickening in
both marrow and spleen (Figure 6F). Overall, these data suggest
that loss of 1 copy of Abi1 markedly accelerates the MPLW515L-
mediated MPN in mice.
Discussion
Extensive evidence implicates dysregulated JAK/STAT sig-
naling in the pathophysiology of MPNs. Nonetheless, JAK2
inhibitors do not have salutary disease-modifying effects at the
stem cell level.7-10 The cross talk between JAK/STAT, MAPK,
and Akt pathways, and the potential of therapeutic targeting of
these pathways, has received much less attention.39,51-53 In-
flammation signaling and cytokine involvement in MPNs,
particularly PMF, is widely acknowledged; however, the spe-
cific role of NF-kB signaling in MPNs was highlighted only
recently.54
Abi-1 is an adapter protein involved in regulation of Abl1,
PI3K, and Ras signaling, with a previously unknown role in
hematopoiesis.12,17,49 To address this gap, we generated bone
marrow-specific murine knockout of Abi1. Loss of Abi-1 proved
sufficient to induce a MPN-like phenotype that replicates many
features of human myelofibrosis. Myeloid hyperplasia, mega-
karyocytosis, progressive fibrosis, splenomegaly, and extra-
medullary hematopoiesis observed in Abi-1KO mice resemble
other murine models of PMF.6,39,55-58 Notably, we observed no
transformation to acute leukemia, yet Abi-1KO animals had
shorter lifespan and evidence of cytokine dysregulation. Al-
though there was no significant phenotypic effect of heterozy-
gous Abi-1 loss, given that PMF typically develops in patients
older than 55 years (equivalent to 18 months in mice), we
continue observation of the effect of heterozygous Abi1 loss in
mice beyond 72 weeks of age.
Molecular analyses of the MPN-like phenotype in Abi-1KO mice
showed unexpectedly only modest activation of JAK2-STAT5
signaling, with hyperactivation of SFKs, STAT3, and NF-kB.
Upregulation of Mpo, integrin aMb2, Runx1, Hck, Fgr, STAT3,
and NF-kB–haptoglobin, seen in proteomic analysis, are con-
sistent with increase in myeloid cells and upregulated SFKs,
STAT3, and NF-kB signaling in Abi-1KO mice. Further work will
be needed to elucidate how overactive SFKs/STAT3/NF-kB
signaling relates to established MPN models. JAK2, MPL, or
CALRmutations are frequent events in MPNs,5,6,39,59 and murine
Figure 6 (continued) gross pathology images of femurs, spleens, and livers of the animals from each experimental group are shown. (C) Average spleen and liver sizes of
Abi-1WT/MPLWT, Abi-1HET/MPLWT, Abi-1WT/MPLW515L, or Abi-1HET/MPLW515L mice. Relative organ weight was calculated as an absolute organ weight (g)/body weight on sacrifice
day (g) 3100. Organs from 6 animals per group were evaluated. (D) Average white blood cell count and hematocrit and platelet count of Abi-1WT/MPLWT, Abi-1HET/MPLWT,
Abi-1WT/MPLW515L, or Abi-1HET/MPLW515L mice. Peripheral blood from 6 animals per groupwas analyzed. (E) Average frequencies ofMac11/Gr-11, CD411, CD421, CD711/Ter1191
or CD711/Ter1192 as well as B2201 and CD31 cells in the bone marrow or peripheral blood obtained from Abi-1WT/MPLWT, Abi-1HET/MPLWT, Abi-1WT/MPLW515L, or Abi-1HET/
MPLW515L mice. Samples from 6 animals per group were analyzed. (F) Gomori reticulin staining of the bone marrow from femurs and spleen sections of Abi-1WT/MPLW515L or Abi-
1HET/MPLW515L animals (black stain). Bars correspond to 100 mm. Images were obtained using Zeiss Axiophot microscope with Zeiss Pan-Apochromat 203/1.0 lens. *P , .05
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models incorporate these variants.39,51,56,57,60-62 In contrast to
JAK2V617F models that progress to secondary myelofibrosis via PV-
like stage,51,60,61,63 our model resembles the thrombopoietin -driven
models expressingMPLW515L or CALRdel52, inwhich fibrosis develops
after a period of primary thrombocytosis.39,56,57,62 To explore the
association between Abi-1 deficiency and established patho-
genetic mechanisms in MPNs, we assessed how heterozygous
loss of Abi-1 affected the MPLW515L-mediated mouse model.
Results showed accelerated MPN-like disease in Abi-1HET/
MPLW515L animals. These data support a contributory role of
Abi-1 to the pathophysiology of MPNs. In addition to these
findings, proteomics and immunoblotting (supplemental
Figure 9E) indicated upregulation of calreticulin in Abi-1KO.
Calreticulin has an established role in MPN pathophysiology,
and somatic CALR mutations occur in 30% of PMF.59 At this
point, the contribution of increased calreticulin to the Abi-1
loss-dependent phenotype remains unclear. Strikingly, Abi-1
deficiency in hematopoietic stem/progenitor cells results in
upregulation of genes controlled, directly or indirectly, by
NF-kB. Genome-wide expression profiling of Abi-1KO LSK
cells highlighted overexpression of pro-inflammatory path-
ways associated with NF-kB activation. Upregulation of pro-
inflammatory cytokines in patients with PMF,64 as well as TLR
activation,65 may contribute to marrow fibrosis. Our data support
a mechanism in which Abi-1 loss results in upregulation of SFKs,
which in turn activate STAT3, ultimately modulating the NF-kB
pathway. Notably, STATs can be activated by SFKs,66,67 and
STAT3 and NF-kB pathways are linked.68,69 Interestingly, Ser-32-
phosphorylated IkB is not degraded and remains highly
expressed in Abi-1KO marrow. IkB phosphorylation on Tyr al-
lows NF-kB activation without IkB degradation.70 Elucidation
of how Abi-1 loss might lead to increased NF-kB signaling and
the role of IkB phosphorylation in this process will require
further research.
Abi-1 loss induced significant impairment of the hemostasis of
HSCs. Increased cell cycle activity of Abi-1KO hematopoietic
stem/progenitor cells is possibly leading to their expansion,
displacement from the marrow, and progressive exhaustion,
and is reflected in their impaired self-renewal capacities.
Similarly, increased cycling and impaired self-renewal of HSCs
was noted in animal models of hematopoietic tissue-specific
overactivation of Akt or NF-kB.71,72 Given the activity of Mx1
promotor-driven Cre in mesenchymal stromal cells, it is rea-
sonable to expect that changes in homeostasis of Abi-1KO HSCs
may prove to be both intrinsic and nonautonomous in future
experiments.
Analyses of ABI1 transcripts in MPNs indicated that its loss may
be specific to PMF. Mechanisms responsible for loss of ABI1
transcripts in PMF are however not clear. Notably, single nu-
cleotide polymorphism arrays performed on 151 MPN samples
showed microdeletions in the 10p12 region encompassing ABI1
locus.73 Sequencing of ABI1 is warranted to provide mutational
profile of the gene in MPNs.
In aggregate, our data provide the first evidence for a role of Abi-1
in the pathogenesis of PMF, and a link to upregulation of the SFKs/
STAT3/NF-kB signaling axis. To our knowledge, this is the first
model of MPN mechanistically uncoupled from JAK2-STAT5
hyperactivity. Full elucidation of the cross-communication be-
tween JAK/SFKs/STAT3/NF-kB signaling may provide insight
into the association between proliferative and pro-inflammatory
features that characterize MPNs, particularly PMF. Targeting
Abi-1 and associated pathways may offer a new therapeutic
strategy for human PMF.
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